CTLA4 and metastatic melanoma: The current standard of care therapies for metastatic melanoma includes immune checkpoint inhibitors (ICIs), a novel class of therapeutics that inhibit cytotoxic T lymphocyte antigen-4 (CTLA-4) or the programmed death-1 receptor/ligand (PD-1/PD-L1).